

## Scientific program

### Sunday 21 August 2016

14:30 – 18:00	Registration desk (Boulevard foyer) Conference sessions (Boulevard Auditorium)
15:30 – 16:00	<b>WELCOME TO COUNTRY</b> <b>CONFERENCE OPENING</b> <i>France Mentré, Chair of the WCoP Executive Committee</i> <b>WELCOME TO DELEGATES</b> <i>Stefanie Hennig, Chair WCoP Local Organizing Committee</i>
16:00 – 17:00	<b>KEYNOTE PRESENTATION</b> Chair: Stefanie Hennig <b>The big world challenges for pharmacometrics - #100 Prof Mats Karlsson, Uppsala University, Sweden</b>
17:00 – 18:00	<b>WELCOME RECEPTION</b> (Boulevard foyer)

### Monday 22 August 2016

08:00 – 17:00	Registration desk (Boulevard foyer) Conference sessions (Boulevard Auditorium)
08:00 – 09:00	<b>POSTER VIEWING</b> (Boulevard foyer)
09:00 – 10:00	<b>KEYNOTE PRESENTATION</b> Chair: Carl Kirkpatrick <b>Challenges in treating infectious disease - linking epidemiology with pharmacometrics - #101 Dr Steve Kern, Global Health – Integrated Development, USA</b>
10:00 – 10:25	Morning tea (Boulevard foyer)
10:30 – 12:00	<b>SYMPOSIUM 1</b> <b>The optimal design, analysis, and translation of infectious disease human challenge models</b> (Facilitated by Carl Kirkpatrick and Craig Rayner)
10:30 – 10:35	Opening remarks
10:35 – 10:55	<b>Developing next-generation malaria medicines to address drug resistance and increase the operational feasibility of malaria elimination efforts - #102 David Reddy, Medicines for Malaria Venture, Switzerland</b>
10:55 – 11:05	<b>Pharmacometric modelling of antimalarial drugs in development: from challenge to clinics - #103 Nathalie Gobeau, Medicines for Malaria Venture, Switzerland</b>
11:05 – 11:15	<b>Pharmacometric modelling of antimalarial drugs in development - #104 Joel Tarning, Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand</b>
11:15 – 11:30	<b>Introduction to human challenge models for respiratory viruses and the application of quantitative pharmacology to enhance drug development - #105 Craig Rayner, d3 Medicine LLC and Monash University, Australia</b>
11:30 – 11:45	<b>Challenges and pitfalls of building models for Flu/RSV and respiratory viruses - #106 Kashyap Patel, Monash-d3 medicine, Australia</b>
11:45 – 12:00	<b>A population model for respiratory syncytial virus (RSV) kinetics using transit compartments based on human challenge data - #107 Julia Korell, Model Answers, Australia</b>
12:00 – 13:25	Lunch (Boulevard foyer) <b>POSTER PRESENTATIONS (12:15 – 13:15)</b> 1. The optimal design, analysis, and translation of infectious disease human challenge models 2. Hospital-based pharmacometrics 3. Language, libraries and connectors 9. Other (abstracts #221 – #226)
13:30 – 15:00	<b>SYMPOSIUM 2</b> <b>Hospital-based pharmacometrics</b> (Facilitated by Kyungsoo Park and Yusuke Tanigawara)
13:30 – 13:35	Opening remarks
13:35 – 13:50	<b>Evaluation of linezolid-induced thrombocytopenia based on hospital pharmacometrics - #108 Yasuhiro Tsuji, University of Toyama, Japan</b>
13:50 – 14:10	<b>NextDose: a web-based collaborative tool for target concentration intervention - #109 Sam Holford, University of Auckland, New Zealand</b>
14:10 – 14:30	<b>Modeling tumor size and survival in patients with metastatic gastric cancer - #110 Dong Woo Chae, Yonsei University, Korea</b>
14:30 – 14:45	<b>Road to individualising tacrolimus therapy in solid organ transplant recipients - #111 Christine Staats, The University of Queensland, Australia</b>
14:45 – 15:00	<b>Understanding the influence of vitamin K on warfarin dosing requirements - #112 Qing-Xi Ooi, University of Otago, New Zealand</b>
15:00 – 15:25	Afternoon tea (Boulevard foyer)
15:30 – 17:00	<b>SYMPOSIUM 3</b> <b>Language, libraries and connectors</b> (Facilitated by Mats Karlsson and Nick Holford)
15:30 – 15:35	Opening remarks
15:35 – 15:55	<b>How can users benefit from the DDMoRe common language standard and interoperability framework? - #113 Phylinda Chan, Pfizer, United Kingdom</b>
15:55 – 16:15	<b>What purpose is the DDMoRe library serving? - #114 Inaki Troconiz, University of Navarra, Spain</b>
16:15 – 16:35	<b>Would a certification process for models published on the DDMoRe repository serve the modelling community? - #115 Siv Jönsson, Uppsala University, Sweden</b>
16:35 – 17:00	<b>What advanced methods and algorithms are promoted through DDMoRe? - #116 Andrew Hooker, Uppsala University, Sweden</b>
17:00 –	Evening at leisure

**Tuesday 23 August 2016**

08:30 – 17:00	<b>Registration desk</b> (Boulevard foyer) <b>Conference sessions</b> (Boulevard Auditorium)
08:00 – 09:00	<b>POSTER VIEWING</b> (Boulevard foyer)
09:00 – 10:00	<b>KEYNOTE PRESENTATION</b> Chair: Lena Friberg <b>Why MIC is poison for the mind - #117 Prof Hartmut Derendorf, University of Florida, USA</b>
10:00 – 10:25	<b>Morning tea</b> (Boulevard foyer)
10:30 – 12:00	<b>SYMPOSIUM 4</b> <b>Bridging the gap between pharmacometricians and statisticians</b> (Facilitated by France Mentré)
10:30 – 10:35	<b>Opening remarks</b>
10:35 – 10:55	<b>Pharmacometricians and statisticians in drug development: can't we all just get along? - #118 Stacey Tannenbaum, Astellas, USA</b>
10:55 – 11:25	<b>When statistics and pharmacometrics join forces for advanced quantitative drug development: A case study - #119 Emmanuel Zuber, Novartis Pharma, Switzerland</b>
11:25 – 11:45	<b>Regulatory-endorsed M&amp;S platforms: The case of Alzheimer Disease CTS - #120 Klaus Romero, Critical Path Institute, USA</b>
11:45 – 12:00	<b>Pharmacometrics, biostatistics and computational biology postgraduate training: How can we integrate courses? - #121 Julie Simpson, The University of Melbourne, Australia</b>
12:00 – 13:25	<b>Lunch</b> (Boulevard foyer) <b>POSTER PRESENTATIONS</b> (12:15 – 13:15) 4. Bridging the gap between pharmacometricians and statisticians 5. Pharmacometric approaches to optimize dose selection 6. Application of models for solid tumor dynamics to oncology drug development 9. Other (abstracts #248 – #253)
13:30 – 15:00	<b>SYMPOSIUM 5</b> <b>Pharmacometric approaches to optimize dose selection</b> (Facilitated by Stacey Tannenbaum)
13:30 – 13:35	<b>Opening remarks</b>
13:35 – 13:55	<b>Recap of the EMA/EFPIA workshop on dose finding - #122 Flora Musuamba Tshinanu, University College London, United Kingdom</b>
13:55 – 14:10	<b>Assessment of Pharmacometric and Statistical Analysis Methods in Dose-Finding Trial Design: Application in Diabetes Drug Development - #123 Timothy Waterhouse, Eli Lilly and Company, USA</b>
14:10 – 14:35	<b>Leaping from plasma and saliva PK to optimize dose selection for optimal drug use - #124 Catherine Sherwin, University of Utah, USA</b>
14:35 – 15:00	<b>Application of a multi-criteria decision analysis model in the dose selection of combination therapy for overactive bladder - #125 Mats Magnusson, Pharmetheus, Sweden</b>
15:00 – 15:25	<b>Afternoon tea</b> (Boulevard foyer)
15:30 – 17:00	<b>SYMPOSIUM 6</b> <b>Application of models for solid tumor dynamics to oncology drug development</b> (Facilitated by Holly Kimko)
15:30 – 15:55	<b>Modeling and simulation with evolving cancer therapies: Combinations, cancer immunotherapy, and more - #126 Jin Yan Jin, Genentech Inc, USA</b>
15:55 – 16:20	<b>Bench-to-bedside translation of antibody drug conjugates (ADCs) using a multiscale mechanistic PK/PD model - #127 Dhaval K Shah, The State University of New York at Buffalo, USA</b>
16:20 – 16:35	<b>Optimization of trial design and dose selection based on the quantitative assessment of the efficacy of TAK-385, an investigational, oral GnRH antagonist, in patients with prostate cancer - #128 Nelleke Snelder, LAP&amp;P Consultants BV, Netherlands</b>
16:35 – 17:00	<b>An analysis of patient-reported outcomes (PRO) in breast cancer patients through item-response theory (IRT) pharmacometric modeling - #129 Emilie Schindler, Uppsala University, Sweden</b>
19:00 – 23:00	<b>CONFERENCE DINNER</b> (Sky Room, Sky level, Brisbane Convention & Exhibition Centre)

**Wednesday 24 August 2016**

08:30 – 15:30	<b>Registration desk</b> (Boulevard foyer) <b>Conference sessions</b> (Boulevard Auditorium)
08:00 – 09:00	<b>POSTER VIEWING</b> (Boulevard foyer)
09:00 – 10:00	<b>KEYNOTE PRESENTATION</b> Chair: Nick Holford <b>From transformative to disruptive - pharmacometrics' crucial role for inferring treatment effectiveness - #130 Prof Carl Peck, University of California San Francisco, USA</b>
10:00 – 10:25	<b>Morning tea</b> (Boulevard foyer)
10:30 – 12:00	<b>SYMPOSIUM 7</b> <b>Influence of body composition and age on pharmacokinetics</b> (Facilitated by Nick Holford and Yusuke Tanigawara)
10:30 – 10:35	<b>Opening remarks</b>
10:35 – 10:55	<b>Using normal fat mass to account for body size and composition - #131 Nick Holford, University of Auckland, New Zealand</b>
10:55 – 11:20	<b>Prediction of fat free mass in adults and children - #132 Hesham Al-Sallami, University of Otago, New Zealand</b>
11:20 – 11:45	<b>The importance of body size for bridging studies - #133 Masato Kaneko, Bayer, Japan</b>
11:45 – 12:00	<b>A simple mechanistic pharmacometric model for HIV in children and adults - #134 Joe Standing, University College London, United Kingdom</b>
12:00 – 13:25	<b>Lunch</b> (Boulevard foyer) <b>POSTER PRESENTATIONS</b> (12:15 – 13:15) 7. Influence of body composition and age on pharmacokinetics 8. Pharmacometrics applications in non-communicable diseases 9. Other (abstracts #266 – #280)
13:30 – 15:00	<b>SYMPOSIUM 8</b> <b>Pharmacometrics applications in non-communicable diseases</b> (Facilitated by Stephen Duffull)
13:30 – 13:35	<b>Opening remarks</b>
13:35 – 13:55	<b>Using a PK/PD modeling approach to optimize the dosing regimen of secukinumab for the treatment of moderate to severe plaque psoriasis - #135 Michael Looby, Novartis, Switzerland</b>
13:55 – 14:20	<b>Population pharmacokinetics and pharmacodynamics of an oral glucagon receptor antagonist to optimize dosing in patients with type 2 diabetes mellitus - #136 Emmanuel Chigutsa, Eli Lilly, USA</b>
14:20 – 14:45	<b>Recommended doses of Levobupivacaine for TAP Blocks: Development of a pharmacokinetic model and estimation of the risk of symptoms of local anesthetic systemic toxicity - #137 Ignacio Cortinez, Pontificia Universidad Católica de Chile, Chile</b>
14:45 – 15:00	<b>A Framework for quantifying the influence of adherence and dose individualization - #138 Piyanan Assawasuwannakit, University of Otago, New Zealand and Mahidol University, Thailand</b>
15:00 – 15:30	<b>CONFERENCE CLOSE</b>